Subscribe
shutterstock_1625917948_nitpicker
nitpicker / Shutterstock.com
5 September 2023Big PharmaMuireann Bolger

Bayer targets Amazon sellers over fake products

Healthcare company accuses online sellers of selling unauthorised over-the-counter products | Consumers leave bad reviews after receiving damaged, expired and poor quality goods, says the complaint | Vory, Sater, Seymour and Pease.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Bayer sues over syringes used in CT scans
23 February 2021   Bayer Healthcare is suing medical devices manufacturer Ecomed Solutions over allegedly patent-infringing syringes.
Big Pharma
Bayer begins $240m AI drug discovery project with Exscientia
10 January 2020   Germany-based Bayer is collaborating with Exscientia, an artificial intelligence (AI)-driven drug discovery company, to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

Trade secrets go global: How brand owners face a high-stakes battlefront
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money
Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations
UK gets new IP minister following cabinet reshuffle